Avalo Therapeutics, Inc. Banner Image

Avalo Therapeutics, Inc.

  • Ticker AVTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Avalo Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Rockville, Maryland
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network. LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokineMore. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, they believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
3.0 / 5.0 (3)

Avalo Therapeutics, Inc. reports have an aggregate usefulness score of 3.0 based on 3 reviews.

Avalo Therapeutics, Inc.

Most Recent Annual Report

Avalo Therapeutics, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Avalo Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!